Results 51 to 60 of about 2,626 (203)

Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study [PDF]

, 2016
BACKGROUND: Asthma is a biologically heterogeneous disease and development of novel therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics and biomarkers in asthma over
C. Porsbjerg, D. Singh, E. S. Barnathan, F. Baribaud, J. M. FitzGerald, J. N. Kline, M. J. Loza, M. Laviolette, null null, P. Berger, P. Chanez, P. E. Silkoff, P. O. Girodet, S. Kelsen, S. Khatri, V. Backer, V. S. Susulic   +16 more
core   +1 more source

Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study [PDF]

, 2023
Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis.
A Balato, A Chiricozzi, AV Marzano, C Conrad, C De Simone, E Ippoliti, G Argenziano, G Caldarola, G Girolomoni, JM Carrascosa, K Peris, L Di Nardo, Luca Bianchi, M Galluzzo, M Maurelli, M Munera Campos, M Ortoncelli, N Gori, S Gkalpakiotis, S Ribero, SM Ferrucci, T Seremet, T Torres   +22 more
core   +1 more source

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Clinical, Cosmetic and Investigational Dermatology, 2022
Katherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC ...
Kelly KA, Perche PO, Feldman SR
doaj  

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo   +2 more
wiley   +1 more source

Current and emerging biologics for the treatment of pediatric atopic dermatitis [PDF]

, 2020
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous lesions, pruritus, and a skin barrier defect.
Balogh, Esther A., Bell, Katheryn A., Feldman, Steven R., Ghamrawi, Rima, Strowd, Lindsay C.   +4 more
core   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough, Fiona McEvoy, Moneeb Saddiq, Michael O'Connell, Maeve Lynch, Brian Kirby, Michelle Murphy   +6 more
wiley   +1 more source

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

Journal of Ophthalmic Inflammation and Infection
Background Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis.
Nenita Maganti, Samuel A. Whittier, Evan J. Warner   +2 more
doaj   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2022
The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh, Mattias A.S. Henning, Gregor B.E. Jemec, Kristina S. Ibler   +3 more
doaj   +1 more source